Phase Ib study of eltrombopag and azacitidine in patients with high‐risk myelodysplastic syndromes and related disorders (the ELASTIC study)

Summary Treating adverse risk myelodysplastic syndromes with azacitidine exacerbates thrombocytopenia. We report a study of eltrombopag in combination with azacitidine using a 3 + 3 cohort design. Patients with baseline platelets of

Saved in:
Bibliographic Details
Published in:British journal of haematology 2022-10, Vol.199 (2), p.222-229
Main Authors: Sternberg, Alexander, Boucher, Rebecca, Coulthard, Helen Chantal, Raghavan, Manoj, Culligan, Dominic, Jackson, Aimee, Cargo, Catherine, Dennis, Mike, Metzner, Marlen, O'Sullivan, Jennifer, Moore, Rachel, Bowen, David, Vyas, Paresh
Format: Article
Language:English
Subjects:
azacitidine
Azacitidine - therapeutic use
Benzoates - therapeutic use
Bone marrow
Drug Combinations
eltrombopag
Hematology
Humans
Hydrazines - therapeutic use
Myelodysplastic syndrome
myelodysplastic syndromes (MDS)
Myelodysplastic Syndromes - drug therapy
Patients
Platelets
Pyrazoles - therapeutic use
Thrombocytopenia
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Treating adverse risk myelodysplastic syndromes with azacitidine exacerbates thrombocytopenia. We report a study of eltrombopag in combination with azacitidine using a 3 + 3 cohort design. Patients with baseline platelets of
ISSN:0007-1048
1365-2141
DOI:10.1111/bjh.18389